Litcius/Paper detail

Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma

Tong Liu, Yao Jin, Mei Dong

2023Clinical Genitourinary Cancer10 citationsDOI

Topics & Concepts

CabozantinibNivolumabMedicineRenal cell carcinomaOncologyKidney cancerCost effectivenessInternal medicineCancerImmunotherapyRisk analysis (engineering)Renal cell carcinoma treatmentEconomic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life
Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma | Litcius